Related Experiment Video
Updated: Jul 5, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
[P53 protein expression and chemosensitivity to cisplatin in patients with non-small cell lung cancer: a
Jin-liang Wang1, Shun-chang Jiao, Ping Ye
1Department of Medical Oncology, General Hospital of PLA, Beijing 100853, China. wangjl301@yahoo.com.cn
Objective:
To explore the relation between p53 protein expression and chemosensitivity to cisplatin in patients with non-small cell lung cancer (NSCLC).
Methods:
The DerSimonian-Laird random effect model was used to analyze the data reported in relevant literature.
Results:
Sixteen trials involving 1070 patients were retrieved. The overall positivity rate of p53 was 50.4% and overall response rate to cisplatin was 38.7%. The test for heterogeneity showed that all eligible studies had heterogeneity (chi 2-/+47.57, P<0.0001). The combined odds ratio (OR) was 1.37, with 95% confidence interval of 0.84-2.24.
Conclusion:
Expression of p53 protein in patients with NSCLC is not associated with the chemosensitivity to cisplatin.
